N/A
N=30,901
Healthcare Disparities in Alopecia Areata
Alopecia Areata
Bottom Line
View on ClinicalTrials.gov: NCT05727306 ↗Enrolled (actual)
30,901
Serious AEs
—
Results posted
Jun 2025
Primary outcome: Primary: Likelihood of Depressive Episodes — 1217; 3576 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- No intervention (Other)
- Age
- Pediatric, Adult, Older Adult · 12+ yrs
- Sex
- All
- Sponsor
- Momentum Data
- Primary completion
- Jul 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Likelihood of Depressive Episodes |
1217; 3576 | — |
| PRIMARY Likelihood of Recurrent Major Depressive Disorder |
835; 2264 | — |
| PRIMARY Likelihood of Anxiety Disorder |
1113; 3188 | — |
| SECONDARY Relative Incidence of Primary Care Attendances |
39034; 109052 | — |
| SECONDARY Relative Incidence of Dermatology Referrals |
1352; 743 | — |
| SECONDARY Relative Incidence Psychological Therapy |
248; 672 | — |
| SECONDARY Relative Incidence of Unemployment |
89; 209 | — |
| SECONDARY Relative Incidence of Time Off Work |
884; 2268 | — |
Summary
Alopecia areata (AA) is a common immune-mediated non-scarring alopecia often associated with substantial morbidity. There are however, limited population-based data on potential disparities in the burden of AA, including across people of different ethnicities and deprivation.
We aimed to provide the first large-scale, population-based estimate of lifetime risk of AA overall and by important sociodemographic subgroups. As AA is associated with an increased burden of mental health conditions and work-related outcomes (unemployment, time off work), a detailed understanding of the burden of disease in different sociodemographic groups is vital to plan resource provision.
Eligibility Criteria
Inclusion Criteria
- Patients aged greater than 12 over the study period.
- Registered with the contributing primary care practice for any duration during the study period
Exclusion Criteria
- People diagnosed with AA before the study period.
Data sourced from ClinicalTrials.gov (NCT05727306). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.